RICHTER.BD
Full HouseAI neutralGedeon Richter PLC · Healthcare · Hungary · $7.3B cap · $8.1M/day traded
HUF 12,960.00 +0.7% · close 9 Nov · scored 11 Nov
Full House: Strong business, sensible price, and the market agrees.
As of 11 Nov 2026, the MoatMap Score for Gedeon Richter PLC (RICHTER.BD) is 97/100, ranked against 25,000+ stocks in 38 markets (Quality 84, Value 58, Momentum 68, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Gedeon Richter is a central and eastern European pharmaceutical manufacturer with established global commercial royalties in psychiatric treatments and an expanding specialty women's healthcare portfolio. The business generates consistent operating margins and low-leverage cash flows, but current intelligence lacks a catalyst for accelerated multiple re-rating or transformative market inflection over the next 18 months.
ABOUT GEDEON RICHTER PLC
Read
Gedeon Richter PLC is a multinational specialty pharmaceutical company headquartered in Budapest, specializing in women's healthcare, central nervous system disorders, and biotechnology. The company possesses robust research and development capabilities, highlighted by its blockbuster anti-psychotic cariprazine (Vraylar) partnered with AbbVie, alongside an established presence in European biosimilars. It operates as the largest pharmaceutical manufacturer in Hungary and a leading women's healthcare specialist globally.
FINANCIAL SUMMARY (HUF)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 802.8B | 805.2B | 857.5B | 929.0B | 5.0% | 941.8B |
| EPS (HUF) | 907.00 | 860.00 | 1,307 | 1,271 | 11.9% | 1,285 |
| Shares | 185.9M | 182.8M | 182.4M | 182.4M | -1.9% | 182.4M |
| Debt | 22.4B | 24.9B | 27.4B | 26.1B | 5.2% | 26.4B |
| Equity | 1.1T | 1.1T | 1.3T | 1.4T | 9.6% | — |
| Op CF | 186.0B | 123.7B | 279.4B | 276.4B | 14.1% | 280.2B |
| Inv CF | -118.8B | -20.0B | -68.8B | -91.9B | — | — |
| Fin CF | -46.9B | -103.8B | -155.2B | -103.0B | — | — |
Above its 200-day average and 4% below its 52-week high.
Calmer than 90% of stocks we rank over the past year (volatility 21% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RICHTER.BD are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| RICHTER.BD | Gedeon Richter PLC(you) | $7.3B | 97 |
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.